ADAPTIMMUNE LLC

Preoperative chemoradiotherapy did not improve survival over perioperative chemotherapy alone in resectable gastric and gastroesophageal junction adenocarcinoma, according to TOPGEAR data. Median overall survival was 46.4 months vs 49.4 months, with no significant differences in progression-free survival. However, preoperative chemoradiotherapy significantly improved pathological outcomes, including complete response rates and tumor downstaging.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

Autolus Therapeutics' obe-cel, an autologous CAR-T cell therapy for relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia, awaits FDA approval on November 16, 2024. The therapy targets CD-19 and has shown a 78% ORR in the FELIX study, with potential peak revenues of ~$300m. Despite a 25% share price drop, Autolus holds $700m in cash and has partnerships with BioNTech, Moderna, and Bristol Myers Squibb, positioning it for future growth.

FDA approved afami-cel, a T-cell receptor therapy, for metastatic synovial sarcoma. It uses genetically engineered T cells to target MAGE-A4 protein in cancer cells, showing tumor shrinkage in 43% of patients with a median response duration of 6 months. Similar to CAR T-cell therapies, it addresses a high need for new treatments in this rare cancer.